Lee Jeea, Go Jieon, Lee Suk Jun, Kwon Yonghan, Kim Nam Hee, Kim Jee Ye, Park Hyung Seok
Department of Surgery, Graduate School of Medicine, Yonsei University College of Medicine, Seoul, Korea.
Department of Surgery, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, Korea.
Cancer Res Treat. 2025 May 7. doi: 10.4143/crt.2025.115.
Oncologic and surgical outcomes of robot-assisted nipple-sparing mastectomy (RNSM) compared to conventional NSM (CNSM) is under investigation. This study compared the clinical outcomes of recurrence-free survival and postoperative complication after RNSM and CNSM.
We retrospectively reviewed data of 401 patients who underwent da Vinci Si/Xi/SP-assisted RNSM or CNSM with immediate reconstruction between November 2016 and November 2020 at a single institute. Oncological outcomes were collected until March 2022. Primary endpoints were long-term outcomes, such as local recurrence, distant metastasis, disease-free survival, overall survival, and postoperative complications, while secondary endpoints were pathology results, and oncological outcomes.
Patients underwent RNSM (n=162) or CNSM (n=239). Of RNSM cases, 9 (5.6%) were performed using the da Vinci Si System, 96 (59.3%) using the da Vinci Xi System, and 57 (35.2%) using the da Vinci SP System. No significant difference in recurrence-free survival was found between the RNSM and CNSM group, and both groups had a median follow-up of 37 months. The recurrence rate in RNSM patients after a median follow-up of 24.5 months was 3.8%, compared with 5.9% in CNSM patients after a median follow-up of 42 months. No difference in recurrence was seen among RNSM patients with respect to surgical systems (multiport vs. SP, p =0.136). In addition, grade III postoperative complication rate was lower in patients with RNSM than in those with CNSM. Transfusion was only applied in 6.2% of patients.
Robot-assisted surgical systems can be safely used to perform NSM in patients with early breast cancer.
正在研究机器人辅助保留乳头乳房切除术(RNSM)与传统保留乳头乳房切除术(CNSM)相比的肿瘤学和手术结果。本研究比较了RNSM和CNSM术后无复发生存率和术后并发症的临床结果。
我们回顾性分析了2016年11月至2020年11月在单一机构接受达芬奇Si/Xi/SP辅助RNSM或CNSM并立即重建的401例患者的数据。收集肿瘤学结果至2022年3月。主要终点是长期结果,如局部复发、远处转移、无病生存期、总生存期和术后并发症,次要终点是病理结果和肿瘤学结果。
患者接受了RNSM(n = 162)或CNSM(n = 239)。在RNSM病例中,9例(5.6%)使用达芬奇Si系统进行,96例(59.3%)使用达芬奇Xi系统进行,57例(35.2%)使用达芬奇SP系统进行。RNSM组和CNSM组之间在无复发生存率方面未发现显著差异,两组的中位随访时间均为37个月。RNSM患者在中位随访24.5个月后的复发率为3.8%,而CNSM患者在中位随访42个月后的复发率为5.9%。RNSM患者在手术系统方面(多端口与SP,p = 0.136)复发情况无差异。此外,RNSM患者的III级术后并发症发生率低于CNSM患者。仅6.2%的患者接受了输血。
机器人辅助手术系统可安全用于早期乳腺癌患者的NSM手术。